DGMT - Tao Chen E07796 possible CDER funding Sequencing contract
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- tbd@fda.gov
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration (FDA) is forecasting a new contract opportunity for Research and Development in Biotechnology, specifically focusing on a sequencing contract associated with Tao Chen's project E07796 and potential CDER funding. The estimated solicitation release date is February 1, 2026, with an anticipated contract award date of April 1, 2026, targeting NAICS code 541714 for biotechnology research and development services.
While specific award values and precise contract details are currently not available, the opportunity involves the FDA's Center for Drug Evaluation and Research (CDER) and appears to be centered on biotechnological research. Primary points of contact include Joshua Holliday (joshua.holliday@fda.hhs.gov) from the FDA, with an additional placeholder contact email of tbd@fda.gov. The contract does not appear to have a specific set-aside designation, suggesting it will be open to a broad range of potential contractors with expertise in biotechnology research and sequencing technologies.
Forecast text
DGMT - Tao Chen E07796 possible CDER funding Sequencing contract
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast